Chapter 41: Anti-inflammatory Agents
initial response to injury
mediators: autacoids release
histamine
serotonin
bradykinin
prostaglandins
leukotrienes
precedes immune response development
activation of immune cells and responds to antigenic substances/ organisms
acute or chronic inflammatory responses
Inflammation may be beneficial or harmful (chronic)
Mediators of chronic inflammation
IL-1, IL-2, IL-3 (interleukins)
GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor)
TNF-a (tumor necrosis factor alpha)
Interferons
PDGF (platelet-derived growth factor)
Example: clinical condition involving chronic inflammation:
Clinical Characteristics:rheumatoid arthritis
Pain
Bone/cartilage destruction
Significant disability
Reduced lifespan
Cellular Damage associated with inflammation:
leukocytes release → lysosomal enzymes
precursors release → arachidonic acid
eicosanoid synthesis
kinins, neuropeptides, histamine
complement components, cytokines
neutrophil membrane produces free radicals:
superoxide anion (from reduction of molecular oxygen) → hydrogen peroxide; hydroxyl radicals
agents interacting with arachidonic acid→ chemotactic factors→ inflammatory response continuation
Varied: actions on blood vessels; nerve endings; cells involved in the inflammatory response
cyclooxygenase isozyme (COX-II): catalyzes prostaglandin synthesis by cells involved in inflammation.
COX-II selective inhibition: advantageous in management of inflammation
Celecoxib (Celebrex) is an example of a nonsteroidal antiinflammatory drug that works as a result of prostaglandin synthesis inhibition (inhibition COX-II)
another cyclooxygenase isozyme (COX-I): catalyzes prostaglandin synthesis by other cells.
eosinophils
neutrophils
macrophages
nonsteroidal antiinflammatory drugs: important role
most nonopioids (aspirin) -- anti-inflammatory effects
appropriate for chronic/acute management of inflammation
Reducing on-going tissue damage
Nonsteroidal antiinflammatory drugs
Nonopioid analgesics (aspirin)
Glucocorticoids
powerful anti-inflammatory action
toxicities prevent use for chronic anti-inflammatory management
useful for control of acute exacerbations
Slow-acting antirheumatic drugs (SAARDs)
Disease-modifying antirheumatic drugs (DMARDs)
weak organic acids
inhibit prostaglandin biosynthesis
may decrease free radicals production
may decrease superoxide production
may alter cellular cAMP concentration
probably do not affect the disease course
aspirin |
salicylate |
apazone |
diclofenac |
diflusnisal |
etodolac |
fenoprofen |
flubiprofen |
ibuprofen |
indomethacin |
ketoprofen |
ketorolac |
oxaprozin |
meclofenamate |
nabumetone (pro-drug) |
naproxen |
piroxicam |
sulindac |
tolmetin |
Chemistry/Pharmacokinetics--aspirin/salicylates
Salicylic acid; acetylsalicyclic acid
salicylic acid:simple organic acid; pKa 3.0
aspirin (acetylsalicyclic acid); pKa 3.5
equally effective: anti-inflammatory action
analgesic: aspirin -- maybe more effective
rapidly absorbed: stomach and upper small intestine
peak plasma salicylates level: 1-2 hours
at stomach pH: salicylates --mainly nonionized, favoring absorption
at higher gastric pH (3.5 or higher by buffering): less gastric irritation
rapidly hydrolyzed → acetic acid + salicylate, catalyzed by tissue/blood esterases
most converted to water-soluble conjugates; renally cleared
saturated pathway: small increase in aspirin dose; significant plasma levels
urine alkalinization excretion of free salicylate
Lower dose aspirin (< 600 mg): first order elimination kinetics; half-life: 3--5 hours
Higher dose aspirin: zero-order (capacity-limited) and first-order mixture
Anti-inflammatory doses (> 4 grams per day), probably capacity-limited; half-life: > 12 hours
inhibition of cyclooxygenase {prostaglandin synthase}
Prostaglandin synthase: catalyzes arachidonic acid → endoperoxide compounds
action of salicylate (cyclooxygenase inhibitor; oxygen radical scavenger)
Aspirin (in certain doses):
reduces prostaglandin formation
reduces thromboxane A2 formation
does not affect leukotriene synthesis
not a selective COX-II inhibitor
Anti-inflammatory Effects:aspirin
reduced synthesis: eicosanoid mediators
interference: kallikrein system mediators
inhibits granulocyte adherence to damaged vasculature
stabilizes lysosomes
inhibits polymorphonuclear leukocyte/macrophage migration to inflammation sites
Effective for management of mild to moderate pain
Pain may arise from:
musculature
dental work
vascular
postpartum conditions
arthritis
bursitis
Sites of action:
peripherally -- sites of inflammation
subcortical sites
"normal" temperature: slightly affected
"elevated" temperature: reduced
Mechanisms of Antipyretic Action:
vasodilation (superficial vessels): heat dissipation
Fever associated with infection: mechanism
Prostaglandin production in the CNS: induced by bacterial pyrogens
Interleukin 1: produces a hypothalamic effect which increases temperature
Interleukin 1: produced by macrophages; released during inflammation; activates lymphocytes
Aspirin blocks:
pyrogen-induced prostaglandin production
CNS response to interleukin 1
Reduced hemostasis;
Mechanism of Action:
Inhibition of platelet aggregation because of thromboxane synthesis inhibition
Aspirin: -- longer antiplatelet duration of effect compared to:
ticlopidine
dipyridamole
Analgesia/Anti-inflammatory Effects
Commonly used for management of mild to moderate pain
Often sold in combination with other agents (combination agents -- not shown more effective or less toxic than aspirin monotherapy)
Management of poisonings (overdosage) involving combinations: more difficult
Particular issues:
Phenacetin-aspirin combinations:
Phenacetin may cause interstitial nephritis (renal impairment)
Aspirin -- Not Effective for :
management of severe visceral pain, e.g. -- acute abdomen, pericarditis, myocardial infarction (antiplatelet action may be useful), renal colic.
Aspirin in combination with opioid analgesics: effective management of some cancer pain.
anti-inflammatory effects of aspirin act to enhance opioid analgesia
High-dose Salicylates have significant anti-inflammatory properties making them useful in treatment of:
rheumatic fever
rheumatoid arthritis
other inflammatory joint diseases
Antipyretic Activity:
Elevated Body Temperature: generally not a useful defense mechanism (exceptions: neurosyphilis, chronic brucellosis)
Aspirin -- best drug for reducing fever if needed; and without contraindications present
Antiplatelet:
reduce incidence of transient ischemic attacks (prophylaxis)
reduce incidence of unstable angina in males (prophylaxis)
may reduce frequency of coronary artery bypass graft thrombosis
may reduce incidents of coronary artery thrombosis
gastric mucosal irritation (undissolved tablet)
stomach absorption of nonionized salicylate
inhibition of protective prostaglandins
reduced/absent prostaglandin may make gastric mucosa more likely to be damaged
misoprostol: decreased frequency to peptic ulceration recurrence in patients taking large NSAIDs dosages
Upper GI bleeding associated with aspirin: erosive gastritis
fecal blood loss: slightly increased with aspirin (normal one ml→ four mls)
Management:
appropriate buffering (food; antacids)
Central Nervous System Effects:
High doses: "Salicylism"
tinnitus
decreased hearing
vertigo
Higher doses: hyperpnea (increaset respiration rate)-- medullary effect
low toxic salicylate levels: initial respiratory alkalosis (due to increased ventilation)
accumulation of salicylic acid derivatives + respiratory depression → acidosis
aspirin doses < 2 grams/day: increase serum uric acid levels
aspirin doses > 4 grams/day: ¯ decrease urate levels < 2.5 mg/dL
mild, typically asymptomatic hepatitis--typically in patients with:
systemic lupus erythematosus
juvenile & adult rheumatoid arthritis
reversible decrease in glomerular filtration rates (patients usually have underlying renal dysfunction)
Large doses: vascular dilation; depression of cardiac function
Hypersensitivity reactions: -- leukotriene-mediated
asthma patients
patients with nasal polyps
associated: bronchoconstrictions/shock
Contraindications: hemophilia
Not typically recommended: in pregnant women
Aspirin in children during/immediately after viral infection: associated with increased risk of Reye's syndrome: use acetaminophen
gastric lavage
if patient hyperthermic: alcohol sponges/ice packs
manage acid-based abnormality
insure high urine volume
urine alkalinization (sodium bicarbonate infusion) promotes salicylate excretion
Promote salicylate intoxication when ingested concurrently:
acetazolamide
ammonium chloride
increased bleeding: alcohol
Aspirin displaces drugs from protein binding sites:
tolbutamide
chlorpropamide
nonsteroidal antiinflammatory drugs
methotrexate
phenytoin
probenecid
aspirin reduces: spironolactone pharmacologic action
aspirin --penicillin G competition for tubular secretion
aspirin: inhibits uricosuric effect of:
probenecid
sulfinpyrazone
Primary Reference: Katzung, B. G. and Furst, D. E. Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Nonopioid Analgesics; Drugs Used in Gout, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 578-602. |
Lipsky, P.E. Rheumatoid Arthritis, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 1880-1888. |
Agudelo, C.A. Gout in Medicine for the Practicing Physician, Fourth edition, (Hurst, J. Willis, editor in chief) Appleton & Lange, 1996, pp 223-226. |
|
|
|